Solid form of an anti-endothelial growth factor receptor (EGFR) antibodies

Abstract

The invention relates to solid forms of antibodies against the Endothelial growth factor (EGF)recep¬tor, in particular precipitates and crystals of monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), which result in biologically active antibody protein through dissolution or suspension in aqueous medium, obtainable by precipitation of the antibody and / or one of its variants and / or fragments dissolved or suspended in aqueous medium by means of a precipitation reagent. The invention furthermore relates to pharmaceutical preparations comprising at least one solid form of the above-mentioned antibodies in precipitated non-crystalline, precipitated crystalline or in soluble or sus¬pended form, and optionally excipients and / or adjuvants and / or further pharmaceutical active ingredients, and to a process for the preparation of solid forms of anti-EGFR antibodies according to the invention.